Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

06 janv. 2026 09h07 HE | Source: Research and Markets

Bio/Pharmaceutical Outsourcing Market Research Report, November 2025: Transforming US Drug Access and Production - MFN Pricing Deals and Historic Manufacturing Investments

Dublin, Jan. 06, 2026 (GLOBE NEWSWIRE) -- The "Bio/Pharmaceutical Outsourcing Report, November 2025" report has been added to ResearchAndMarkets.com's offering.The Bio/Pharmaceutical Outsourcing...
06 janv. 2026 08h19 HE | Source: Coeptis Therapeutics

Coeptis Therapeutics S-4 Declared Effective by SEC, Proxy Mailing Begins in Anticipation of the Merger Transaction with Z Squared

WEXFORD, Pa., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (“Coeptis” or the “Company”), a next-gen technology and biopharmaceutical company, , announced...
05 janv. 2026 10h24 HE | Source: Research and Markets

Gene Therapy R&D Market Forecast Report 2025-2035: Focus on Cancer, Rare Diseases, Cardiovascular, Ophthalmic, Haematology, Neurological, Diabetes Mellitus

Dublin, Jan. 05, 2026 (GLOBE NEWSWIRE) -- The "Gene Therapy R&D Market Report 2025-2035" has been added to ResearchAndMarkets.com's offering. Overall world revenue for the Gene Therapy...
05 janv. 2026 07h00 HE | Source: Marker Therapeutics

Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer

Clinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.6% disease control rate in patients with pancreatic cancer in Arm A of the clinical study Study...
29 déc. 2025 09h15 HE | Source: Longeveron

Longeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026

Longeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Week 2026.
19 déc. 2025 16h04 HE | Source: NurExone Biologic Inc

NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis

TORONTO and HAIFA, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) today announced new laboratory data...
18 déc. 2025 09h57 HE | Source: Research and Markets

Cryopreservation Bags and Freezing Bags Market Trends and Global Forecasts to 2035: Distribution by Type of Analyte Stored and Key Geographical Regions

Dublin, Dec. 18, 2025 (GLOBE NEWSWIRE) -- The "Cryopreservation Bags and Freezing Bags Market: Industry Trends and Global Forecasts - Distribution by Type of Analyte Stored and Key Geographical...
18 déc. 2025 09h53 HE | Source: Research and Markets

Cell Therapy Media Market to Nearly Triple by 2035, Reaching $4.5 Billion, Fueled by Advancements in FDA-Approved Cell Therapies for Various Diseases

Dublin, Dec. 18, 2025 (GLOBE NEWSWIRE) -- The "Cell Therapy Media Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Product, Type of Cell Therapy, Scale of Operation,...
12 déc. 2025 04h50 HE | Source: Research and Markets

Global Fill Finish Manufacturing Market to Hit USD 28.14 Billion by 2030, Driven by Regulatory Compliance and Automation Needs

Dublin, Dec. 12, 2025 (GLOBE NEWSWIRE) -- The "Fill Finish Manufacturing Market by Product ((Consumables (PFS (Glass), Plunger Stopper), Vial (RTU, Polymer), Vial Stoppers (RTU), Cartridge, Cell...
11 déc. 2025 07h00 HE | Source: https://immatics.com/

Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress

IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across all dose levelsEncouraging early clinical anti-tumor...

Page suivante